Salarius Pharmaceuticals Stock Today
| SLRX Stock | USD 1.45 0.33 29.46% |
PerformanceWeak
| Odds Of DistressHigh
|
Salarius Pharmaceuticals is trading at 1.45 as of the 26th of February 2025; that is 29.46 percent increase since the beginning of the trading day. The stock's open price was 1.12. Salarius Pharmaceuticals has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 27th of January 2025 and ending today, the 26th of February 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 29th of January 2015 | Category Healthcare | Classification Health Care |
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company has 1.58 M outstanding shares of which 19.34 K shares are at this time shorted by private and institutional investors with about 0.0 trading days to cover. More on Salarius Pharmaceuticals
Moving together with Salarius Stock
| 0.73 | A | Agilent Technologies Earnings Call Today | PairCorr |
Moving against Salarius Stock
Salarius Stock Highlights
| President CEO | David MBA | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsSalarius Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Salarius Pharmaceuticals' financial leverage. It provides some insight into what part of Salarius Pharmaceuticals' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Salarius Pharmaceuticals (SLRX) is traded on NASDAQ Exchange in USA. It is located in 2450 Holcombe Boulevard, Houston, TX, United States, 77021 and employs 2 people. Salarius Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 1.77 M. Salarius Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 1.58 M outstanding shares of which 19.34 K shares are at this time shorted by private and institutional investors with about 0.0 trading days to cover.
Salarius Pharmaceuticals currently holds about 22.65 M in cash with (12.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 10.09, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Salarius Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationAbout 92.48 % of Salarius Pharmaceuticals outstanding shares are held by general public with 2.29 (%) owned by insiders and only 5.23 % by institutional holders.
Check Salarius Ownership Details
Salarius Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Ubs Group Ag | 2024-12-31 | 7.1 K | |
| Advisor Group Holdings, Inc. | 2024-12-31 | 162 | |
| Bank Of America Corp | 2024-12-31 | 11.0 | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 7.0 | |
| Blackrock Inc | 2024-12-31 | 1.0 | |
| Sbi Securities Co Ltd | 2024-12-31 | 1.0 | |
| Wells Fargo & Co | 2024-09-30 | 0.0 | |
| Tower Research Capital Llc | 2024-12-31 | 0.0 | |
| Northern Trust Investments N A | 2024-12-31 | 0.0 | |
| Armistice Capital, Llc | 2024-09-30 | 0.0 | |
| Citigroup Inc | 2024-12-31 | 0.0 |
Salarius Pharmaceuticals Historical Income Statement
Salarius Stock Against Markets
Salarius Pharmaceuticals Corporate Executives
Elected by the shareholders, the Salarius Pharmaceuticals' board of directors comprises two types of representatives: Salarius Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Salarius. The board's role is to monitor Salarius Pharmaceuticals' management team and ensure that shareholders' interests are well served. Salarius Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Salarius Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
Additional Tools for Salarius Stock Analysis
When running Salarius Pharmaceuticals' price analysis, check to measure Salarius Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Salarius Pharmaceuticals is operating at the current time. Most of Salarius Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Salarius Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Salarius Pharmaceuticals' price. Additionally, you may evaluate how the addition of Salarius Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.